Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fusion Antibodies Plc (GB:FAB)
LSE:FAB
Holding GB:FAB?
Track your performance easily
FAB Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range2.80p - 9.50p
Previous Close3.25p
Volume455.46K
Average Volume (3M)841.94K
Market Cap
£3.10M
Enterprise Value2.98M
Total Cash (Recent Filing)£195.00K
Total Debt (Recent Filing)£75.00K
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Sep 05, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding95,370,000
10 Day Avg. Volume540,957
30 Day Avg. Volume841,941
Standard Deviation0.23
R-Squared0.00565
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)1.08
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Fusion Antibodies Plc News
PremiumCompany Announcements
Fusion Antibodies Plc Announces Annual Report & AGM
PremiumCompany Announcements
Fusion Antibodies CSO Ups Shareholding
PremiumCompany Announcements
Fusion Antibodies to Present at Shard Capital EventPremiumCompany Announcements
Fusion Antibodies CEO Increases Shareholding
PremiumCompany Announcements
Fusion Antibodies Reports Challenging yet Optimistic FY24
PremiumCompany Announcements
Fusion Antibodies Expands Collaboration with NCIPremiumCompany Announcements
Fusion Antibodies Chair Ups Stake
PremiumCompany Announcements
Fusion Antibodies Unveils Interactive Investor HubOptions Prices
Currently, No data available
---
Ownership Overview
9.35% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
90.65% Public Companies and
Individual Investors
FAB FAQ
What was Fusion Antibodies Plc’s price range in the past 12 months?
Fusion Antibodies Plc lowest share price was 2.80p and its highest was 9.50p in the past 12 months.
What is Fusion Antibodies Plc’s market cap?
Currently, no data Available
When is Fusion Antibodies Plc’s upcoming earnings report date?
Fusion Antibodies Plc’s upcoming earnings report date is Sep 05, 2024 which is 15 days ago.
How were Fusion Antibodies Plc’s earnings last quarter?
Fusion Antibodies Plc released its earnings results on Dec 04, 2023. The company reported -0.029p earnings per share for the quarter, missing the consensus estimate of N/A by -0.029p.
Is Fusion Antibodies Plc overvalued?
According to Wall Street analysts Fusion Antibodies Plc’s price is currently Overvalued.
Does Fusion Antibodies Plc pay dividends?
Fusion Antibodies Plc does not currently pay dividends.
What is Fusion Antibodies Plc’s EPS estimate?
Fusion Antibodies Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fusion Antibodies Plc have?
Fusion Antibodies Plc has 95,365,560 shares outstanding.
What happened to Fusion Antibodies Plc’s price movement after its last earnings report?
Fusion Antibodies Plc reported an EPS of -0.029p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 11.864%.
Which hedge fund is a major shareholder of Fusion Antibodies Plc?
Currently, no hedge funds are holding shares in GB:FAB
---
Fusion Antibodies Plc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.22%
12-Months-Change
Fundamentals
Return on Equity
-152.67%
Trailing 12-Months
Asset Growth
17.36%
Trailing 12-Months
Company Description
Fusion Antibodies Plc
Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression.
---
Technical Analysis
---